bit.bio

United Kingdom
Cambridge, England, United Kingdom, CB2 0AX

Company profile

bit.bio company profile

Bit.bio provides engineered human cell products and platform services for biomedical research, drug discovery, and cell therapy development. The company uses a precision cell programming system to convert stem cells into defined human cell types and supplies a portfolio of reprogrammed cells, custom cell development services, and research-ready human cell models for scientific and pharmaceutical use. Bit.bio also supports integration of its products into partner research ecosystems and offers platform capabilities that help identify transcription factors for specific cell states. Its focus includes enabling scalable access to human cell models for experiments, screening workflows, and therapeutic investigation.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
CB2 0AX
Country code
GB
Continent
Europe

Capital profile

Funding and company signals

Funding stage
Late Stage Venture
Funding rounds
6
Total equity funding
$225M
Last funding
Series C / $50M / 2026-01-09
Last equity funding
Series C / $50M
Investors
19
Lead investors
3
Founders
2
Articles
85

Founders and investors

Founders

Florian SchusterMark Kotter

Lead investors

Jonathan MilnerM&G InvestmentsRick Klausner

Investors

ARCH Venture PartnersBlueYard CapitalCharles River Laboratories InternationalForesite CapitalTencent